Journey Medical Co. (NASDAQ:DERM – Get Free Report) Director Lindsay A. Md Rosenwald acquired 10,000 shares of Journey Medical stock in a transaction that occurred on Monday, March 25th. The stock was acquired at an average cost of $3.04 per share, for a total transaction of $30,400.00. Following the completion of the purchase, the director now directly owns 144,245 shares of the company’s stock, valued at $438,504.80. The acquisition was disclosed in a filing with the SEC, which is available through this link.
Journey Medical Stock Performance
Journey Medical stock opened at $3.89 on Thursday. Journey Medical Co. has a 12 month low of $1.02 and a 12 month high of $8.11.
Analysts Set New Price Targets
Separately, Alliance Global Partners started coverage on Journey Medical in a research report on Friday, February 16th. They issued a “buy” rating and a $8.50 target price for the company.
Hedge Funds Weigh In On Journey Medical
Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. grew its stake in Journey Medical by 78.1% during the fourth quarter. Vanguard Group Inc. now owns 129,448 shares of the company’s stock worth $746,000 after purchasing an additional 56,781 shares during the period. Virtu Financial LLC acquired a new stake in Journey Medical in the fourth quarter valued at approximately $153,000. Northern Trust Corp acquired a new stake in Journey Medical in the fourth quarter valued at approximately $96,000. Finally, Citadel Advisors LLC purchased a new position in shares of Journey Medical during the fourth quarter valued at approximately $65,000. 7.25% of the stock is currently owned by institutional investors.
About Journey Medical
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant acne; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; Zilxi, a topical minocycline treatment for inflammatory lesions; Ximino, an oral minocycline drug for the treatment of moderate to severe acne; and Exelderm cream and solution for topical use.
Further Reading
- Five stocks we like better than Journey Medical
- How to Start Investing in Real Estate
- Krispy Kreme’s Sweet Deal: McDonald’s Partnership Sparks Growth?
- 3 REITs to Buy and Hold for the Long Term
- Bitcoin Depot Falls Into Value Territory With Expansion Underway
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- 7 Stocks That Will Drive the Weight Loss Drugs Market
Receive News & Ratings for Journey Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Journey Medical and related companies with MarketBeat.com's FREE daily email newsletter.